Results 1 to 10 of about 17,709 (191)
, 2020 Abstract Myelofibrosis is a reactive process common to many malignant and benign disorders. Primary myelofibrosis is a chronic myeloproliferative neoplasm arising in a pluripotent haematopoietic stem cell. It results in abnormalities in red cell, granulocyte, and platelet production in association with marrow fibrosis and ...
Carmelo J. Blanquicett +1 more
+6 more sources
From primary myelofibrosis to chronic myeloid leukemia, BCR::ABL1+ B‐Lymphoblastic leukemia, and back to primary myelofibrosis: An illustration of dynamic clonal evolution [PDF]
eJHaemThe simultaneous detection of BCR::ABL1 and JAK2 V617F was rarely reported and their clonal relationship and dynamic clonal shift were not characterized. Here, we described a unique case with the initial presentation as JAK2 V617F+ primary myelofibrosis,
Devin Wang +3 more
doaj +2 more sources
Hepatology, EarlyView., 2022 Mesenchymal stem cells subset, educated by TNF‐α, are involved to generate inflammatory microenvironment and promote hepatocarcinogenesis Abstract Background and Aims Increasing evidence suggests that mesenchymal stem cells (MSCs) home to injured local tissues and the tumor microenvironment in the liver.
Chen Zong +9 more
wiley +1 more source
Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis
Hepatology, EarlyView., 2022 Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres +21 more
wiley +1 more source
Disseminated tuberculosis with myelofibrosis presentation: a case report
Journal of Medical Case Reports, 2021 Background Primary myelofibrosis is a rare myeloproliferative disorder in middle-aged and old adults and should be distinguished from secondary and reactive causes of bone marrow fibrosis because, in reactive fibrosis, treatment approaches depend on the ...
Mahdi Khatuni +3 more
doaj +1 more source
Pediatric immune myelofibrosis (PedIMF) as a novel and distinct clinical pathological entity
Frontiers in Pediatrics, 2022 Myelofibrosis is a rare myeloproliferative disorder. The detailed descriptions of myelofibrosis in children and adolescents is limited to a few case series and case reports describing fewer than 100 patients, thus suggesting the extreme rarity of this ...
Fabiola Guerra +12 more
doaj +1 more source
Journal of Gastrointestinal and Abdominal Radiology, 2021 Objective Myelofibrosis is a rare chronic myelolymphoproliferative disease and is associated with increased risk of venous thromboembolism. The objective of this study is to retrospectively evaluate patients with primary myelofibrosis who underwent ...
Marco Di Girolamo +5 more
doaj +1 more source
Treatment of primary myelofibrosis
Turkish Journal of Hematology, 2009 Şinasi Özsoylu
doaj +2 more sources
Haematologica, 2010 Primary myelofibrosis shows histological and pathogenetic overlap with essential thrombocythemia and polycythemia vera. Several diagnostic classifications have been proposed for primary myelofibrosis, although little is known about their clinical utility.
Philip A. Beer +2 more
doaj +1 more source
Haematologica, 2015 Primary myelofibrosis is characterized by clonal myeloproliferation, dysmegakaryopoiesis, extramedullary hematopoiesis associated with myelofibrosis and altered stroma in the bone marrow and spleen.
Christophe Desterke +16 more
doaj +1 more source